A flexible platform accessible in flexible ways.

Ksilink’s primary objective is to deliver pre-clinical candidates (PCC) and further, through proprietary programs or through strategic collaborations.

Connect-to-Translate-to-Market

Drug discovery is a sport for which you need to complete all positions. We therefore have designed a partnering approach where we offer many entry doors to engage with all kinds of partners and to cope with their own constraints: industry, academia, SMEs… To allow to partner with the best, we have built a flexible platform accessible in flexible ways.

Ksilink’s for hospitals & research

We enable scientists to translate the fruit of their early research into tangible assets for the benefit of patients and society. Launching a drug discovery project with Ksilink means you access a synergistic, multidisciplinary and open-minded network with top level expertise in translational science. Together, we can add substantial value to your project and preparing it to enter pharmaceutical drug development.

Ksilink for industrial players

You can have access to most of our projects at every moment and secure options to increase your R&D pipeline. We may also start a drug discovery program or target discovery program in a strategic collaboration.

Typical deal terms

Ksilink mitigates resources and risks through strategic collaborations from which expect upfront payments, milestones, and royalties.

Contact: Mona Boyé